Morgan Stanley Issues Positive Forecast for Personalis (NASDAQ:PSNL) Stock Price

Personalis (NASDAQ:PSNL) had its target price lifted by Morgan Stanley from $9.00 to $13.00 in a research report released on Thursday morning,Benzinga reports. The firm currently has an equal weight rating on the stock.

A number of other equities analysts have also recently commented on the company. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. BTIG Research decreased their target price on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $11.67.

Personalis Price Performance

Shares of PSNL opened at $14.65 on Thursday. The firm has a market cap of $1.53 billion, a P/E ratio of -14.36 and a beta of 2.24. The stock has a 50 day simple moving average of $9.81 and a two-hundred day simple moving average of $8.62. Personalis has a 1 year low of $3.84 and a 1 year high of $15.36.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The business had revenue of $15.47 million for the quarter, compared to analysts’ expectations of $14.48 million. On average, equities analysts anticipate that Personalis will post -1.06 earnings per share for the current year.

Insider Transactions at Personalis

In other Personalis news, CEO Christopher M. Hall sold 100,000 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $15.08, for a total value of $1,508,000.00. Following the completion of the sale, the chief executive officer directly owned 235,986 shares in the company, valued at $3,558,668.88. This trade represents a 29.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of Personalis stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $14.00, for a total value of $69,748.00. Following the sale, the chief financial officer directly owned 198,833 shares in the company, valued at approximately $2,783,662. The trade was a 2.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 435,032 shares of company stock worth $5,599,929 in the last ninety days. Insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in PSNL. Aberdeen Group plc lifted its stake in shares of Personalis by 36.1% in the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after buying an additional 861,948 shares in the last quarter. Oracle Investment Management Inc. bought a new stake in shares of Personalis during the third quarter valued at approximately $1,496,000. Howland Capital Management LLC increased its position in shares of Personalis by 65.5% during the fourth quarter. Howland Capital Management LLC now owns 547,115 shares of the company’s stock valued at $4,355,000 after acquiring an additional 216,442 shares in the last quarter. Next Century Growth Investors LLC purchased a new position in Personalis in the 4th quarter worth approximately $4,970,000. Finally, D.A. Davidson & CO. purchased a new position in Personalis in the 4th quarter worth approximately $1,158,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.